Cheol K. Chung

Cheol K. Chung

Auto-generated profile, based on publicly available information

Cheol K. Chung

Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2022 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
TBTamas Benkovics
Tamas Benkovics
FPFeng Peng
Feng Peng
EPEric M. Phillips
Eric M. Phillips
CAChihui An
Chihui An
RBRachel S. Bade
Rachel S. Bade
FXFeng Xu
Feng Xu

23 December 2022 in Green Chemistry
Verified
Journal Article
Closed access
PDF file
NKNadine Kuhl
Nadine Kuhl
BTBen W. H. Turnbull
Ben W. H. Turnbull
YJYining Ji
Yining Ji
RLReed T. Larson
Reed T. Larson
MSMichael Shevlin
Michael Shevlin
DTDavid A. Thaisrivongs
David A. Thaisrivongs
The development of a protecting group-free, 2-step synthesis of 5-amino-2-hydroxymethyltetrahydropyran 1a from biorenewable Cyrene™ is described which renders access to BTK-inhibitor nemtabrutinib (2) more efficient and sustainable.

21 August 2018 in Organic Letters
Verified
Journal Article
Closed access
JWJens Wolfard
Jens Wolfard
JXJie Xu
Jie Xu
HZHaiming Zhang
Haiming Zhang
CCCheol K. Chung
Cheol K. Chung

7 May 2026 in Science
Verified
Journal Article
Closed access
AKArtis Klapars
Artis Klapars
AFAnna Fryszkowska
Anna Fryszkowska
SGStephanie Galanie
Stephanie Galanie
OAOmer Ad
Omer Ad
EAEllen Y. Aguilera
Ellen Y. Aguilera
WZWendy Zhong
Wendy Zhong
Historically, many compelling therapeutic targets have been accessible only by injectable biologic drugs. Macrocyclic peptides, such as the proprotein convertase subtilisin/kexin type 9 inhibitor enlicitide for the treatment of atherosclerotic cardiovascular disease, are beginning to unlock these targets to orally administered therapies to enable broader patient access. We report the convergent biocatalytic assembly of enlicitide from simple building blocks enabled by a suite of engineered enzymes to catalyze selective peptide fragment formation, coupling, and macrocyclization in a protecting group–free manner. Together with efficient crystallizations that obviate the need for chromatography, this approach reduces the number of steps by greater than half compared with prior state-of-the-art methods, addressing long-standing synthetic challenges and offering a sustainable blueprint for the scalable development of complex peptide therapeutics.

15 December 2023 in Organic Process Research & Development
Verified
Journal Article
Closed access
MMMichael J. Di Maso
Michael J. Di Maso
JKJeffrey Kuethe
Jeffrey Kuethe
KNKarthik Narsimhan
Karthik Narsimhan
MBMatthew Burris
Matthew Burris
CCCheol K. Chung
Cheol K. Chung
DZDaniel Zewge
Daniel Zewge

6 July 2022 in Organic Letters
Verified
Journal Article
Closed access
MPMichael T. Pirnot
Michael T. Pirnot
EMEdna Mao
Edna Mao
YLYu Hong Lam
Yu Hong Lam
JLJohn Limanto
John Limanto
RCRyan D Cohen
Ryan D Cohen
EPEric M. Phillips
Eric M. Phillips